131 related articles for article (PubMed ID: 27974211)
21. Dendropanoxide Alleviates Thioacetamide-induced Hepatic Fibrosis via Inhibition of ROS Production and Inflammation in BALB/
Kundu A; Gali S; Sharma S; Kacew S; Yoon S; Jeong HG; Kwak JH; Kim HS
Int J Biol Sci; 2023; 19(9):2630-2647. PubMed ID: 37324954
[TBL] [Abstract][Full Text] [Related]
22. Network pharmacology-based analysis of Resinacein S against non-alcoholic fatty liver disease by modulating lipid metabolism.
Mao FF; Gao SS; Huang YJ; Zhou N; Feng JK; Liu ZH; Zhang YQ; Yuan LY; Wei G; Cheng SQ
Front Nutr; 2023; 10():1076569. PubMed ID: 36866057
[TBL] [Abstract][Full Text] [Related]
23. Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta-analysis.
Li S; Wang X; Li Q; Li C
Oncol Lett; 2023 Jan; 25(1):19. PubMed ID: 36478896
[TBL] [Abstract][Full Text] [Related]
24. Protein phosphatases regulate the liver microenvironment in the development of hepatocellular carcinoma.
Yoon JS; Lee CW
Exp Mol Med; 2022 Nov; 54(11):1799-1813. PubMed ID: 36380016
[TBL] [Abstract][Full Text] [Related]
25. A New View of Activating Mutations in Cancer.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2022 Nov; 82(22):4114-4123. PubMed ID: 36069825
[TBL] [Abstract][Full Text] [Related]
26. Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.
Pan J; Zhou L; Zhang C; Xu Q; Sun Y
Signal Transduct Target Ther; 2022 Jun; 7(1):177. PubMed ID: 35665742
[TBL] [Abstract][Full Text] [Related]
27. Concurrent Disruption of the Ras/MAPK and NF-κB Pathways Induces Circadian Deregulation and Hepatocarcinogenesis.
Hanley KL; Liang Y; Wang G; Lin X; Yang M; Karin M; Fu W; Feng GS
Mol Cancer Res; 2022 Mar; 20(3):337-349. PubMed ID: 34810213
[TBL] [Abstract][Full Text] [Related]
28. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.
Chen WS; Liang Y; Zong M; Liu JJ; Kaneko K; Hanley KL; Zhang K; Feng GS
Cell Rep; 2021 Nov; 37(6):109974. PubMed ID: 34758313
[TBL] [Abstract][Full Text] [Related]
29. SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.
Xia L; Yang F; Wu X; Li S; Kan C; Zheng H; Wang S
Cancer Cell Int; 2021 Jul; 21(1):337. PubMed ID: 34217295
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
[TBL] [Abstract][Full Text] [Related]
31. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
Feng GS; Hanley KL; Liang Y; Lin X
Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):104-114. PubMed ID: 32715491
[TBL] [Abstract][Full Text] [Related]
32. Diet induces hepatocyte protection in fatty liver disease via modulation of PTEN signaling.
Ikeda Y; Murakami M; Nakagawa Y; Tsuji A; Kitagishi Y; Matsuda S
Biomed Rep; 2020 Jun; 12(6):295-302. PubMed ID: 32382414
[TBL] [Abstract][Full Text] [Related]
33. NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21
Williams M; Liu X; Zhang Y; Reske J; Bahal D; Gohl TG; Hollern D; Ensink E; Kiupel M; Luo R; Das R; Xiao H
Oncogene; 2020 May; 39(19):3821-3836. PubMed ID: 32203160
[TBL] [Abstract][Full Text] [Related]
34.
Xu L; Zhou C; Pan R; Tang J; Wang J; Li B; Huang T; Duan S; Xu C
Oncol Lett; 2020 Mar; 19(3):1693-1700. PubMed ID: 32194661
[No Abstract] [Full Text] [Related]
35. PTEN Tumor-Suppressor: The Dam of Stemness in Cancer.
Luongo F; Colonna F; Calapà F; Vitale S; Fiori ME; De Maria R
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366089
[No Abstract] [Full Text] [Related]
36. Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.
Ruckert MT; de Andrade PV; Santos VS; Silveira VS
Cell Mol Life Sci; 2019 Jul; 76(13):2571-2592. PubMed ID: 30982078
[TBL] [Abstract][Full Text] [Related]
37. Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma.
Li N; Zhu Y
Therap Adv Gastroenterol; 2019; 12():1756284818821560. PubMed ID: 30719075
[TBL] [Abstract][Full Text] [Related]
38. A clinical study on the expression of PTEN in renal cell carcinoma in children.
Lu H; Tan Y; Chen L
Oncol Lett; 2019 Jan; 17(1):69-72. PubMed ID: 30655739
[TBL] [Abstract][Full Text] [Related]
39. SHP2-Mediated Signal Networks in Stem Cell Homeostasis and Dysfunction.
Kan C; Yang F; Wang S
Stem Cells Int; 2018; 2018():8351374. PubMed ID: 29983715
[TBL] [Abstract][Full Text] [Related]
40. Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase SHP2 and activating JNK in prostate cells.
Bhattacharyya S; Feferman L; Han X; Ouyang Y; Zhang F; Linhardt RJ; Tobacman JK
J Biol Chem; 2018 Jul; 293(28):11076-11087. PubMed ID: 29794138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
